Gilead and Galapagos’ filgotinib OK’d in Europe for rheumatoid arthritis (NASDAQ:GILD)


As anticipated, the European Fee approves Gilead Sciences’ (GILD -0.5%) and collaboration accomplice Galapagos NV’s (GLPG +3.2%) Jyseleca (filgotinib) for adults with moderate-to-severe rheumatoid arthritis who’ve failed to reply to or are illiberal of a number of disease-modifying anti-rheumatic medication.

Two months in the past, the advisory group CHMP adopted a positive opinion backing the nod.

The JAK1 inhibitor was simply approved in Japan for RA, however the firms will not be fairly there within the U.S. The FDA needs to see data from two ongoing trials, anticipated in H1 2021.

Quant score on GLPG is Very Bearish. 


Please enter your comment!
Please enter your name here